<SEC-DOCUMENT>0001410368-17-001710.txt : 20171127
<SEC-HEADER>0001410368-17-001710.hdr.sgml : 20171127
<ACCEPTANCE-DATETIME>20171127145632
ACCESSION NUMBER:		0001410368-17-001710
CONFORMED SUBMISSION TYPE:	NSAR-B
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170930
FILED AS OF DATE:		20171127
DATE AS OF CHANGE:		20171127
EFFECTIVENESS DATE:		20171127

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEKLA LIFE SCIENCES INVESTORS
		CENTRAL INDEX KEY:			0000884121
		IRS NUMBER:				043147016
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		NSAR-B
		SEC ACT:		1940 Act
		SEC FILE NUMBER:	811-06565
		FILM NUMBER:		171222620

	BUSINESS ADDRESS:	
		STREET 1:		100 FEDERAL STREET
		STREET 2:		19TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
		BUSINESS PHONE:		6177728515

	MAIL ADDRESS:	
		STREET 1:		100 FEDERAL STREET
		STREET 2:		19TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	H&Q LIFE SCIENCES INVESTORS
		DATE OF NAME CHANGE:	19920929
</SEC-HEADER>
<DOCUMENT>
<TYPE>NSAR-B
<SEQUENCE>1
<FILENAME>hqlanswer.fil
<DESCRIPTION>ANSWER FILE
<TEXT>
<PAGE>      PAGE  1
000 B000000 09/30/2017
000 C000000 0000884121
000 D000000 N
000 E000000 NF
000 F000000 Y
000 G000000 N
000 H000000 N
000 I000000 6.1
000 J000000 A
001 A000000 TEKLA LIFE SCIENCES INVESTORS
001 B000000 811-6565
001 C000000 6177728500
002 A000000 100 Federal Street, 19th Floor
002 B000000 BOSTON
002 C000000 MA
002 D010000 02110
003  000000 N
004  000000 N
005  000000 N
006  000000 N
007 A000000 N
007 B000000  0
007 C010100  1
008 A000001 TEKLA CAPITAL MANAGEMENT LLC
008 B000001 A
008 C000001 801-000000
008 D010001 BOSTON
008 D020001 MA
008 D030001 02110
010 A000001 STATE STREET BANK AND TRUST CO.
010 B000001 85-85003
010 C010001 BOSTON
010 C020001 MA
010 C030001 02111
012 A000001 COMPUTERSHARE TRUST CO. N.A.
012 B000001 85-113400
012 C010001 CANTON
012 C020001 MA
012 C030001 02021
013 A000001 DELOITTE & TOUCHE LLP
013 B010001 BOSTON
013 B020001 MA
013 B030001 02110
015 A000001 STATE STREET BANK & TRUST CO.
015 B000001 C
015 C010001 BOSTON
015 C020001 MA
015 C030001 02110
015 E010001 X
018  000000 Y
019 A000000 Y
<PAGE>      PAGE  2
019 B000000    4
019 C000000 TEKLAFUNDS
020 A000001 JP MORGAN CHASE & CO.
020 B000001 13-3224013
020 C000001     66
020 A000002 NATIONAL FINANCIAL SERVICES CORP.
020 B000002 04-2785576
020 C000002     57
020 A000003 BANK OF NEW YORK MELLON
020 B000003 13-5160382
020 C000003     38
020 A000004 WEDBUSH MORGAN SECURITIES, INC.
020 B000004 95-2495390
020 C000004     21
020 A000005 JEFFERIES & CO.
020 B000005 95-2622900
020 C000005     15
020 A000006 WELLS FARGO BANK
020 B000006 94-3379992
020 C000006     11
020 A000007 SANFORD C. BERNSTEIN CO., LLC
020 B000007 13-2625874
020 C000007     10
020 A000008 UBS AG
020 B000008 13-2338166
020 C000008      9
020 A000009 CITIGROUP
020 B000009 13-3082694
020 C000009      9
020 A000010 MIZUHO CORPORATE BANK LTD.
020 B000010 13-5624234
020 C000010      9
021  000000      276
022 A000001 STATE STREET BANK AND TRUST CO.
022 B000001 04-1867445
022 C000001   4421655
022 D000001         0
022 A000002 JPMORGAN CHASE & CO.
022 B000002 13-3224016
022 C000002     64504
022 D000002         0
022 A000003 NEUROVANCE, INC
022 C000003      3826
022 D000003     11433
022 A000004 JEFFERIES
022 B000004 952622900
022 C000004      2697
022 D000004     10051
022 A000005 CITIGROUP
022 B000005 13-3082694
022 C000005      6750
<PAGE>      PAGE  3
022 D000005         0
022 A000006 AMPHIVENA THERAPEUTICS, INC.
022 C000006      2100
022 D000006         0
022 A000007 CANTOR FITZGERALD & CO.
022 B000007 13-3680184
022 C000007      1505
022 D000007         0
022 A000008 PIPER JAFFRAY & CO.
022 B000008 41-0953246
022 C000008      1275
022 D000008         0
022 A000009 DYNEX TECHNOLOGIES, INC.
022 C000009         0
022 D000009      1230
022 A000010 MILESTONE PHARMACEUTICALS INC.
022 C000010       900
022 D000010         0
023 C000000    4509780
023 D000000      22714
024  000000 N
025 D000001       0
025 D000002       0
026 A000000 N
026 B000000 Y
026 C000000 N
026 D000000 Y
026 E000000 N
026 F000000 N
026 G010000 N
026 G020000 N
026 H000000 N
027  000000 N
028 A010000         0
028 A020000         0
028 A030000         0
028 A040000         0
028 B010000         0
028 B020000         0
028 B030000         0
028 B040000         0
028 C010000         0
028 C020000         0
028 C030000         0
028 C040000         0
028 D010000         0
028 D020000         0
028 D030000         0
028 D040000         0
028 E010000         0
028 E020000         0
<PAGE>      PAGE  4
028 E030000         0
028 E040000         0
028 F010000         0
028 F020000         0
028 F030000         0
028 F040000         0
028 G010000         0
028 G020000         0
028 G030000         0
028 G040000         0
028 H000000         0
030 A000000      0
030 B000000  0.00
030 C000000  0.00
031 A000000      0
031 B000000      0
032  000000      0
033  000000      0
035  000000      0
036 B000000      0
038  000000      0
042 A000000   0
042 B000000   0
042 C000000   0
042 D000000   0
042 E000000   0
042 F000000   0
042 G000000   0
042 H000000   0
043  000000      0
044  000000      0
045  000000 Y
046  000000 N
047  000000 N
048  000000  0.000
048 A010000        0
048 A020000 0.000
048 B010000        0
048 B020000 0.000
048 C010000        0
048 C020000 0.000
048 D010000        0
048 D020000 0.000
048 E010000        0
048 E020000 0.000
048 F010000        0
048 F020000 0.000
048 G010000        0
048 G020000 0.000
048 H010000        0
048 H020000 0.000
<PAGE>      PAGE  5
048 I010000        0
048 I020000 0.000
048 J010000        0
048 J020000 0.000
048 K010000        0
048 K020000 0.000
049  000000 N
050  000000 N
051  000000 N
052  000000 N
053 A000000 N
054 A000000 Y
054 B000000 N
054 C000000 Y
054 D000000 N
054 E000000 N
054 F000000 N
054 G000000 N
054 H000000 N
054 I000000 N
054 J000000 Y
054 K000000 N
054 L000000 N
054 M000000 Y
054 N000000 N
054 O000000 N
055 A000000 N
055 B000000 N
056  000000 N
057  000000 N
058 A000000 N
059  000000 Y
060 A000000 N
060 B000000 N
061  000000        0
062 A000000 N
062 B000000   0.0
062 C000000   0.0
062 D000000   0.0
062 E000000   0.0
062 F000000   0.0
062 G000000   0.0
062 H000000   0.0
062 I000000   0.0
062 J000000   0.0
062 K000000   0.0
062 L000000   0.0
062 M000000   0.0
062 N000000   0.0
062 O000000   0.0
062 P000000   0.0
<PAGE>      PAGE  6
062 Q000000   0.0
062 R000000   0.0
063 A000000   0
063 B000000  0.0
066 A000000 Y
066 B000000 N
066 C000000 Y
066 D000000 N
066 E000000 N
066 F000000 N
066 G000000 N
067  000000 N
068 A000000 N
068 B000000 N
069  000000 N
070 A010000 Y
070 A020000 Y
070 B010000 Y
070 B020000 N
070 C010000 N
070 C020000 N
070 D010000 Y
070 D020000 N
070 E010000 N
070 E020000 N
070 F010000 Y
070 F020000 N
070 G010000 Y
070 G020000 N
070 H010000 Y
070 H020000 N
070 I010000 N
070 I020000 N
070 J010000 Y
070 J020000 Y
070 K010000 Y
070 K020000 Y
070 L010000 Y
070 L020000 Y
070 M010000 Y
070 M020000 N
070 N010000 Y
070 N020000 N
070 O010000 Y
070 O020000 N
070 P010000 N
070 P020000 N
070 Q010000 N
070 Q020000 N
070 R010000 Y
070 R020000 N
<PAGE>      PAGE  7
071 A000000    174387
071 B000000    185929
071 C000000    404763
071 D000000   43
072 A000000 12
072 B000000       91
072 C000000     1591
072 D000000        0
072 E000000        0
072 F000000     4305
072 G000000       88
072 H000000        0
072 I000000       53
072 J000000      118
072 K000000      180
072 L000000       53
072 M000000      133
072 N000000        0
072 O000000        0
072 P000000        0
072 Q000000        0
072 R000000      100
072 S000000      201
072 T000000      211
072 U000000        0
072 V000000        0
072 W000000      119
072 X000000     5561
072 Y000000        0
072 Z000000    -3879
072AA000000    45305
072BB000000        0
072CC010000    27129
072CC020000        0
072DD010000        0
072DD020000        0
072EE000000    33491
073 A010000   0.0000
073 A020000   0.0000
073 B000000   1.5900
073 C000000   0.0000
074 A000000      615
074 B000000     9609
074 C000000        0
074 D000000      155
074 E000000    13104
074 F000000   428936
074 G000000        0
074 H000000        0
074 I000000    15176
074 J000000        0
<PAGE>      PAGE  8
074 K000000        0
074 L000000       18
074 M000000      719
074 N000000   468332
074 O000000     1310
074 P000000      380
074 Q000000        0
074 R010000        0
074 R020000        0
074 R030000        0
074 R040000      291
074 S000000        0
074 T000000   466351
074 U010000    21572
074 U020000        0
074 V010000    21.62
074 V020000     0.00
074 W000000   0.0000
074 X000000      182
074 Y000000        0
075 A000000        0
075 B000000   422688
076  000000    21.48
077 A000000 Y
077 B000000 Y
077 C000000 Y
077 D000000 N
077 E000000 N
077 F000000 N
077 G000000 N
077 H000000 N
077 I000000 N
077 J000000 N
077 K000000 N
077 L000000 N
077 M000000 N
077 N000000 N
077 O000000 N
077 P000000 N
077 Q010000 N
077 Q020000 N
077 Q030000 N
078  000000 N
080 A000000 ICI MUTUAL INSURANCE COMPANY
080 C000000     3900
081 A000000 Y
081 B000000   4
082 A000000 Y
082 B000000       25
083 A000000 N
083 B000000        0
<PAGE>      PAGE  9
084 A000000 N
084 B000000        0
085 A000000 Y
085 B000000 N
086 A010000    853
086 A020000  16720
086 B010000     24
086 B020000    407
086 C010000      0
086 C020000      0
086 D010000      0
086 D020000      0
086 E010000      0
086 E020000      0
086 F010000      0
086 F020000      0
087 A010000 TEKLA LIFE SCIENCES INVESTORS
087 A020000 87911K100
087 A030000 HQL
088 A000000 N
088 B000000 N
088 C000000 N
088 D000000 N
SIGNATURE   LAURA WOODWARD
TITLE       TREASURER

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.77B ACCT LTTR
<SEQUENCE>2
<FILENAME>HQLex77b.txt
<DESCRIPTION>AUDIT LETTER
<TEXT>
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Trustees and Shareholders of
Tekla Life Sciences Investors

In planning and performing our audit of the financial
statements of Tekla Life Sciences Investors (the "Fund") as
of and for the year ended September 30, 2017, in
accordance with the standards of the Public Company
Accounting Oversight Board (United States) (PCAOB), we
considered the Fund's internal control over financial
reporting, including controls over safeguarding securities,
as a basis for designing our auditing procedures for the
purpose of expressing our opinion on the financial
statements and to comply with the requirements of Form N-
SAR, but not for the purpose of expressing an opinion on
the effectiveness of the Fund's internal control over
financial reporting. Accordingly, we express no such opinion.

The management of the Fund is responsible for establishing
and maintaining effective internal control over
financial reporting. In fulfilling this responsibility,
estimates and judgments by management are required to assess
the expected benefits and related costs of controls. A
fund's internal control over financial reporting is a process
designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of
financial statements for external purposes in accordance
with generally accepted accounting principles. A fund's
internal control over financial reporting includes those
policies and procedures that (1) pertain to the maintenance
of records that, in reasonable detail, accurately and
fairly reflect the transactions and dispositions of the
assets of the fund; (2) provide reasonable assurance that
transactions are recorded as necessary to permit preparation
of financial statements in accordance with generally accepted
accounting principles, and that receipts and
expenditures of the fund are being made only in accordance
with authorizations of management and trustees of
the fund; and (3) provide reasonable assurance regarding
prevention or timely detection of unauthorized
acquisition, use, or disposition of a fund's assets that
could have a material effect on the financial statements.

Because of its inherent limitations, internal control over
financial reporting may not prevent or detect
misstatements. Also, projections of any evaluation of
effectiveness to future periods are subject to the risk that
controls may become inadequate because of changes in
conditions or that the degree of compliance with the
policies or procedures may deteriorate.

A deficiency in internal control over financial reporting
exists when the design or operation of a control does not
allow management or employees, in the normal course of
performing their assigned functions, to prevent or
detect misstatements on a timely basis. A material weakness
is a deficiency, or a combination of deficiencies, in
internal control over financial reporting, such that there
is a reasonable possibility that a material misstatement of
a fund's annual or interim financial statements will not be
prevented or detected on a timely basis.

Our consideration of the Fund's internal control over
financial reporting was for the limited purpose described in
the first paragraph and would not necessarily disclose all
deficiencies in internal control that might be material
weaknesses under standards established by the PCAOB. However,
we noted no deficiencies in the Fund's
internal control over financial reporting and its operation,
including controls for safeguarding securities, that we
consider to be a material weakness, as defined above, as of
September 30, 2017.

This report is intended solely for the information and use
of management, the Trustees of Tekla Life Sciences
Investors and the Securities and Exchange Commission and is
not intended to be and should not be used by
anyone other than these specified parties.

DELOITTE & TOUCHE LLP
Boston, Massachusetts
November 20, 2017






</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.77C VOTES
<SEQUENCE>3
<FILENAME>HQLex77c.txt
<DESCRIPTION>VOTING
<TEXT>
HQL


ANNUAL MEETING REPORT:  An Annual Meeting of
Shareholders was held on June 15, 2017.
Shareholders voted to elect Trustees of the
Fund to hold office for a term of three years or
until their respective successors shall have been
duly elected and qualified.  The following votes
were cast with respect to each of the nominees:


				For	  Withheld
Oleg Pohotsky, MBA, J.D.   18,714,751	  552,967
William S. Reardon     	   18,766,073	  501,645

Oleg Pohotsky, MBA, J.D. and William S. Reardon
were elected to serve until the 2020 Annual
Meeting.

Trustees serving until the 2018 Annual Meeting are
Daniel R. Omstead, Ph.D. and Lucinda H.
Stebbins, CPA.

Trustees serving until the 2019 Annual Meeting are
Michael W. Bonney, Rakesh K. Jain, Ph.D.
and Uwe E. Reinhardt, Ph. D.

Shareholders ratified the appointment of Deloitte
& Touche LLP as the independent registered
public accountants of the Fund for the fiscal
year ending September 30, 2017 by the following
votes:

For			Against		Abstain
18,852,213		190,061		225,445



Shareholders opposed a shareholder proposal
regarding annual terms of trustees by the following
votes:

For		Against		Abstain		Non-Votes
2,992,916	4,988,619	432,040		10,854,144







</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
